Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,827 | -13,916 | -5,638 | -16,590 | -15,432 |
| Depreciation Amortization | 16 | 11 | 6 | 40 | 39 |
| Accounts receivable | 49 | 25 | 70 | N/A | 242 |
| Accounts payable and accrued liabilities | 3,986 | 2,738 | 3,362 | N/A | 2,078 |
| Other Working Capital | 4,566 | 4,541 | 3,267 | -2,650 | 334 |
| Other Operating Activity | -3,752 | -2,599 | -3,358 | 300 | -2,037 |
| Operating Cash Flow | $-13,964 | $-9,200 | $-2,291 | $-18,900 | $-14,776 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -33 | -9 | -5 | -30 | -39 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -1,000 |
| Sale Of Investment | 1,500 | 1,500 | 1,542 | N/A | 5,950 |
| Other Investing Activity | 0 | 0 | 0 | 5,690 | 0 |
| Investing Cash Flow | $1,467 | $1,491 | $1,537 | $5,660 | $4,911 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 100 | 100 | N/A | N/A | N/A |
| Common Stock Issued | 44,269 | 304 | N/A | N/A | 7 |
| Other Financing Activity | -3,445 | 0 | 0 | 15,190 | 0 |
| Financing Cash Flow | $40,923 | $404 | $N/A | $15,190 | $7 |
| Beginning Cash Position | 15,646 | 15,646 | 15,646 | 13,690 | 13,693 |
| End Cash Position | 44,072 | 8,340 | 14,891 | 15,640 | 3,835 |
| Net Cash Flow | $28,427 | $-7,305 | $-755 | $1,950 | $-9,858 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,964 | -9,200 | -2,291 | -18,900 | -14,776 |
| Capital Expenditure | -33 | -9 | -5 | N/A | -39 |
| Free Cash Flow | -13,997 | -9,209 | -2,297 | -18,900 | -14,815 |